Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Global Point-of-Care Molecular Diagnostics Market to Be Driven by Rising Instances of Infectious Diseases

By LabMedica International staff writers
Posted on 27 Dec 2021

The global market for point-of-care (PoC) molecular diagnostics is predicted to record a solid growth over the next couple of years due to a rise in instances of infectious diseases and increasing public awareness about pre-disease detection. More...

Additionally, growing research and development due to increased funding by both government and private entities, leading to new and better products being rolled out, will also have a positive impact on the market.

These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of market research and consulting services.

PoC testing in diagnostics which mainly entail tests that are portable and generate rapid results is fast gaining traction. Molecular tests that study the genetic material of an infectious disease are gaining maximum traction since they are swift, portable, hassle-free to conduct, and cost less. Hospitals and other healthcare centers are eagerly adopting them because of the convenience they offer. PoC diagnostics finds usage in the domains of oncology, infectious diseases, and hematology and endocrinology. Out of these, infectious diseases are driving most of the demand in the market mainly on account of rising cases of Zika and other viruses causing deadly maladies. Quick unraveling of the causative agents of infectious diseases is the key to treating them successfully. Going forward, progress in DNA sequencing and analysis is expected to further speed up accurate detection of the causative agents. This kind of technological progress is expected to provide a further impetus to the market for PoC diagnostics.

Currently, the market for PoC molecular diagnostics is being dominated by a few top manufacturers. These vendors are competing against one another based on pricing and product quality. They are frequently upgrading their products to more effective ones. However, a key factor posing a challenge to market growth is the duration of time needed for developing molecular diagnostic products. This is because the development process consists of numerous stages involving prototype designing, research, testing, and pre- and post-marketing activities. Besides, complicated regulatory processes are also restraining market growth.

Geographically, the uptake of PoC molecular diagnostics is the highest in North America owing to the increasing occurrence of both cancer and infectious diseases in the region. Another factor that makes North America a market leader is the presence of several key players in the region which has resulted in the introduction of various PoC molecular diagnostics products. However, with new companies entering the fray, competition in the worldwide PoC molecular diagnostics market is set to heat up in the near future.

Related Links:
TMR Research 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.